PH21308A - 3-keto-19-nor-/4,9-steroids - Google Patents

3-keto-19-nor-/4,9-steroids

Info

Publication number
PH21308A
PH21308A PH28558A PH28558A PH21308A PH 21308 A PH21308 A PH 21308A PH 28558 A PH28558 A PH 28558A PH 28558 A PH28558 A PH 28558A PH 21308 A PH21308 A PH 21308A
Authority
PH
Philippines
Prior art keywords
keto
steroids
Prior art date
Application number
PH28558A
Other languages
English (en)
Inventor
Philibert Daniel
Teutsch Jean Georges
Costerousse Germain
Deraedt Roger
Original Assignee
Roussel Uclaf
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Roussel Uclaf filed Critical Roussel Uclaf
Publication of PH21308A publication Critical patent/PH21308A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J1/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
    • C07J1/0051—Estrane derivatives
    • C07J1/0081—Substituted in position 17 alfa and 17 beta
    • C07J1/0088—Substituted in position 17 alfa and 17 beta the substituent in position 17 alfa being an unsaturated hydrocarbon group
    • C07J1/0096—Alkynyl derivatives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J61/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton has been modified by contraction of only one ring by one or two atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J17/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, having an oxygen-containing hetero ring not condensed with the cyclopenta(a)hydrophenanthrene skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J21/00—Normal steroids containing carbon, hydrogen, halogen or oxygen having an oxygen-containing hetero ring spiro-condensed with the cyclopenta(a)hydrophenanthrene skeleton
    • C07J21/005—Ketals
    • C07J21/006—Ketals at position 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J31/00—Normal steroids containing one or more sulfur atoms not belonging to a hetero ring
    • C07J31/006—Normal steroids containing one or more sulfur atoms not belonging to a hetero ring not covered by C07J31/003
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J33/00—Normal steroids having a sulfur-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton
    • C07J33/002—Normal steroids having a sulfur-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton not condensed
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C07J41/0005—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring the nitrogen atom being directly linked to the cyclopenta(a)hydro phenanthrene skeleton
    • C07J41/0016—Oximes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C07J41/0033—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
    • C07J41/0077—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 substituted in position 11-beta by a carbon atom, further substituted by a group comprising at least one further carbon atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C07J41/0033—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
    • C07J41/0077—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 substituted in position 11-beta by a carbon atom, further substituted by a group comprising at least one further carbon atom
    • C07J41/0083—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 substituted in position 11-beta by a carbon atom, further substituted by a group comprising at least one further carbon atom substituted in position 11-beta by an optionally substituted phenyl group not further condensed with other rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C07J41/0033—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
    • C07J41/0094—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 containing nitrile radicals, including thiocyanide radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J51/00—Normal steroids with unmodified cyclopenta(a)hydrophenanthrene skeleton not provided for in groups C07J1/00 - C07J43/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J7/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms
    • C07J7/0005—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21
    • C07J7/001—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by a keto group
    • C07J7/0015—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by a keto group not substituted in position 17 alfa
    • C07J7/0025—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by a keto group not substituted in position 17 alfa substituted in position 16
    • C07J7/003—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by a keto group not substituted in position 17 alfa substituted in position 16 by a saturated or unsaturated hydrocarbon group
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J7/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms
    • C07J7/0005—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21
    • C07J7/001—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by a keto group
    • C07J7/004—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by a keto group substituted in position 17 alfa
    • C07J7/0045—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by a keto group substituted in position 17 alfa not substituted in position 16
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J7/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms
    • C07J7/0005—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21
    • C07J7/0065—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by an OH group free esterified or etherified
    • C07J7/0075—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by an OH group free esterified or etherified substituted in position 17 alfa
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J71/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton is condensed with a heterocyclic ring
    • C07J71/0005—Oxygen-containing hetero ring
    • C07J71/001—Oxiranes

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Toxicology (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Steroid Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
PH28558A 1982-03-01 1983-02-23 3-keto-19-nor-/4,9-steroids PH21308A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR8203338A FR2522328B1 (fr) 1982-03-01 1982-03-01 Nouveaux produits derives de la structure 3-ceto 4,9 19-nor steroides, leur procede de preparation et leur application comme medicaments

Publications (1)

Publication Number Publication Date
PH21308A true PH21308A (en) 1987-09-28

Family

ID=9271439

Family Applications (1)

Application Number Title Priority Date Filing Date
PH28558A PH21308A (en) 1982-03-01 1983-02-23 3-keto-19-nor-/4,9-steroids

Country Status (32)

Country Link
US (2) US4477445A (ja)
JP (2) JPS58201800A (ja)
KR (1) KR880001870B1 (ja)
AR (1) AR241187A1 (ja)
AT (1) AT396109B (ja)
AU (1) AU562739B2 (ja)
BE (1) BE896042A (ja)
CA (1) CA1206471A (ja)
CH (1) CH657368A5 (ja)
DE (1) DE3307143A1 (ja)
DK (1) DK89783A (ja)
EG (1) EG15881A (ja)
ES (1) ES8401495A1 (ja)
FI (1) FI80049C (ja)
FR (1) FR2522328B1 (ja)
GB (1) GB2118186B (ja)
GR (1) GR78465B (ja)
HU (1) HU193269B (ja)
IE (1) IE54748B1 (ja)
IL (1) IL67920A0 (ja)
IT (1) IT1197592B (ja)
LU (1) LU84667A1 (ja)
MA (1) MA19716A1 (ja)
MX (1) MX7199E (ja)
NL (1) NL8300738A (ja)
PH (1) PH21308A (ja)
PT (1) PT76307B (ja)
SE (1) SE8300308L (ja)
SU (1) SU1340593A3 (ja)
WO (1) WO1983003099A1 (ja)
YU (1) YU47883A (ja)
ZA (1) ZA83982B (ja)

Families Citing this family (79)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2528434B1 (fr) * 1982-06-11 1985-07-19 Roussel Uclaf Nouveaux 19-nor steroides substitues en 11b et eventuellement en 2, leur procede de preparation et leur application comme medicament
US5182381A (en) * 1982-03-01 1993-01-26 Roussel Ulcaf Intermediates for 3-keto-19-nor-Δ4,9 -steroids
FR2639045B2 (fr) * 1982-03-01 1994-07-29 Roussel Uclaf Nouveaux produits derives de la structure 3-ceto-delta-4,9-19-nor steroides et leur application comme medicaments
DE3231827A1 (de) * 1982-08-24 1984-03-01 Schering AG, 1000 Berlin und 4709 Bergkamen 11ss-aryl-17(alpha)-alkinyl-17ss-hydroxy-4,9(10)- estradien-3-on-derivate, deren herstellung und diese enthaltende pharmazeutische praeparate
DE3461090D1 (en) * 1983-02-18 1986-12-04 Schering Ag 11-beta-aryl-estradienes, process for their preparation and pharmaceutical compositions containing them
IT1212835B (it) * 1983-08-18 1989-11-30 Lehner Ag Derivati di acidi biliari, procedimento per la loro preparazione e relative composizioni farmaceutiche.
DE3347126A1 (de) * 1983-12-22 1985-07-11 Schering AG, 1000 Berlin und 4709 Bergkamen 11ss-aryl-estradiene, deren herstellung und diese enthaltende pharmazeutische praeparate
US4666898A (en) * 1983-12-28 1987-05-19 Jackson Lab. Treatment of obesity, diabetes and other symptoms of hypercorticoidism using etiocholanolones
DE3410880A1 (de) * 1984-03-21 1985-10-03 Schering AG, Berlin und Bergkamen, 1000 Berlin 17-substituierte estradiene und estratriene
DE3438500C1 (de) * 1984-10-18 1986-05-28 Schering AG, 1000 Berlin und 4709 Bergkamen Verfahren zur Herstellung 11ß-substituierter Δ↑9↑-19-Norsteroide
FR2573657B1 (fr) * 1984-11-29 1989-05-12 Roussel Uclaf Produit comprenant une substance antiprogestomimetique et une substance uterotonique
FR2576025B1 (fr) * 1985-01-14 1987-01-23 Roussel Uclaf Nouveaux steroides substitues en position 10, leur procede et les intermediaires de preparation, leur application comme medicaments, les compositions pharmaceutiques les contenant
AU580843B2 (en) * 1985-02-07 1989-02-02 Schering Aktiengesellschaft 11``-phenyl-gonanes, their manufacture and pharmaceutical preparations containing them
GB8513723D0 (en) * 1985-05-31 1985-07-03 Erba Farmitalia 11-beta substituted steroids
CA1241947A (en) * 1985-05-31 1988-09-13 Pierre R. Proulx Conjugated polyene sterol derivatives as membrane probes
US4686214A (en) * 1985-10-30 1987-08-11 Alcon Laboratories, Inc. Anti-inflammatory compounds for ophthalmic use
FR2598421B1 (fr) * 1986-05-06 1988-08-19 Roussel Uclaf Nouveaux produits 19-nor ou 19-nor d-homo steroides substitues en position 11b par un radical phenyle portant un radical alkynyle, leur procede de preparation, leur application comme medicaments et les compositions les renfermant
DE3625315A1 (de) * 1986-07-25 1988-01-28 Schering Ag 11ss-(4-isopropenylphenyl)-estra-4,9-diene, deren herstellung und diese enthaltende pharmazeutische praeparate
US4774236A (en) * 1986-09-17 1988-09-27 Research Triangle Institute 17α-(substituted-methyl)-17β-hydroxy/esterified hydroxy steroids and pharmaceutical compositions containing them
US5272140A (en) * 1987-01-23 1993-12-21 Akzo N.V. 11-aryl steroid derivatives
FR2610933B1 (fr) * 1987-02-18 1989-06-09 Roussel Uclaf Nouveaux 19-nor steroides substitues en position 7, leur preparation, leur application comme medicaments, les compositions pharmaceutiques les renfermant
DE3708942A1 (de) * 1987-03-18 1988-09-29 Schering Ag 19,11ss-ueberbrueckte steroide, deren herstellung und diese enthaltende pharmazeutische praeparate
US5446178A (en) * 1987-03-18 1995-08-29 Schering Aktiengesellschaft Process for preparing 19,11β-bridged steroids
US5075464A (en) * 1987-04-22 1991-12-24 Merrell Dow Pharmaceuticals Inc. 17β-(cyclopropylamino)androstene derivatives
DE3723788A1 (de) * 1987-07-16 1989-01-26 Schering Ag 11(beta)-phenyl-4,9,15-estratriene, deren herstellung und diese enthaltende pharmazeutische praeparate
FR2618783B1 (fr) * 1987-07-30 1991-02-01 Roussel Uclaf Nouveaux 17-aryle steroides, leurs procedes et des intermediaires de preparation comme medicaments et les compositions pharmaceutiques les renfermant
FR2620707B1 (fr) * 1987-09-18 1989-12-08 Roussel Uclaf Nouveaux steroides comportant un cycle spirannique a 3, 4 ou 6 chainons en position 17, leur procede et des intermediaires de preparation, leur application comme medicaments et les compositions pharmaceutiques les renfermant
US4954490A (en) * 1988-06-23 1990-09-04 Research Triangle Institute 11 β-substituted progesterone analogs
DE3822770A1 (de) * 1988-07-01 1990-01-04 Schering Ag 13-alkyl-11ss-phenylgonane
JPH02188599A (ja) * 1988-11-16 1990-07-24 Roussel Uclaf ３―ケト―デルタ―４，９―１９―ノルステロイドから誘導される新物質及びそれらよりなる薬剤
FR2665901B2 (fr) * 1989-02-24 1994-07-29 Roussel Uclaf Nouveaux 19-nor sterouides ayant en position 11beta une chaine carbonee comportant une fonction amide, leur preparation, leur application comme medicaments.
US6790971B1 (en) * 1989-02-24 2004-09-14 Aventis Pharma S.A. 19-Nor-steroids
FR2643638B1 (fr) * 1989-02-24 1991-06-14 Roussel Uclaf Nouveaux 19-nor steroides ayant en position 11beta une chaine carbonee comportant une fonction amide ou carbamate, leur procede de preparation et les intermediaires de ce procede, leur application comme medicaments et les compositions pharmaceutiques les contenant
ATE172469T1 (de) * 1989-08-04 1998-11-15 Schering Ag 11 beta-aryl-gona-4,9-dien-3-one
US5276023A (en) * 1989-08-08 1994-01-04 Roussel Uclaf 19-nor-steroid esters
FR2651435A1 (fr) * 1989-09-07 1991-03-08 Roussel Uclaf Nouvelle utilisation de composes anti-progestomimetiques.
FR2659233B1 (fr) * 1990-03-06 1994-01-21 Roussel Uclaf Nouvelle utilisation de composes anti-progestomimetiques chez les animaux d'elevage.
DE4008584A1 (de) * 1990-03-15 1991-09-26 Schering Ag Verfahren zur herstellung von zwischenprodukten fuer die antigestagensynthese (onapristonsynthese)
DE4042004A1 (de) * 1990-12-22 1992-06-25 Schering Ag 14(beta)-h-, 14- u. 15-en-11(beta)-aryl-4-estrene
US5407928A (en) * 1990-08-15 1995-04-18 Schering Aktiengesellschaft 11β-aryl-gona-4,9-dien-3-ones
JP3029907B2 (ja) * 1991-12-20 2000-04-10 理化学研究所 抗肥満剤
JP3862295B2 (ja) * 1993-09-30 2006-12-27 独立行政法人理化学研究所 抗肥満剤
US5420120A (en) * 1993-12-17 1995-05-30 Alcon Laboratories, Inc. Anti-inflammatory glucocorticoid compounds for topical ophthalmic use
US5639598A (en) * 1994-05-19 1997-06-17 The Trustees Of The University Of Pennsylvania Method and kit for identification of antiviral agents capable of abrogating HIV Vpr-Rip-1 binding interactions
EP0683172B1 (en) * 1994-05-19 1997-08-13 Akzo Nobel N.V. 11,21-Bisphenyl-19-norpregnane derivatives
US5780220A (en) * 1994-05-19 1998-07-14 Trustees Of The University Of Pennsylvania Methods and compositions for inhibiting HIV replication
DE4434488A1 (de) * 1994-09-14 1996-03-21 Schering Ag Steroidester und -amide, Verfahren zu ihrer Herstellung und ihre pharmazeutische Verwendung
US5929262A (en) * 1995-03-30 1999-07-27 The United States Of America As Represented By The Department Of Health And Human Services Method for preparing 17α-acetoxy-11β-(4-N, N-dimethylaminophyl)-19-Norpregna-4,9-diene-3, 20-dione, intermediates useful in the method, and methods for the preparation of such intermediates
IL118974A (en) * 1995-08-17 2001-09-13 Akzo Nobel Nv History 11 - (Transformed Phenyl) - Astra - 4, 9 - Diane, their preparation and pharmaceutical preparations containing them
US6900193B1 (en) * 1996-05-01 2005-05-31 The United States Of America As Represented By The Department Of Health And Human Services Structural modification of 19-norprogesterone I: 17-α-substituted-11-β-substituted-4-aryl and 21-substituted 19-norpregnadienedione as new antiprogestational agents
CA2253673C (en) * 1996-05-01 2009-09-08 The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services 21-substituted progesterone derivatives as new antiprogestational agents
IL122740A (en) * 1997-01-15 2003-09-17 Akzo Nobel Nv 16-hydroxy-11-(substituted phenyl)-estra-9,4-diene derivatives, their preparation and pharmaceutical compositions containing them
DE19745085A1 (de) * 1997-10-11 1999-04-15 Jenapharm Gmbh 11ß-Benzaldoxim-9alpha,10alpha-epoxy-estr-4-en-Derivate, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende pharmazeutische Präparate
JP3873097B2 (ja) * 1997-11-06 2007-01-24 独立行政法人理化学研究所 抗肥満剤及び脂質代謝改善剤
US6531462B2 (en) 1997-11-06 2003-03-11 Riken Medicament for treating obesity and improving lipid metabolism
US6020328A (en) 1998-03-06 2000-02-01 Research Triangle Institute 20-keto-11β-arylsteroids and their derivatives having agonist or antagonist hormonal properties
US6262042B1 (en) 1998-05-29 2001-07-17 Research Triangle Institute 17β-amino and hydroxylamino-11β-arylsteroids and their derivatives having agonist or antagonist hormonal properties
ES2546291T3 (es) * 2000-03-17 2015-09-22 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services 17-Alfa-sustituida, 11-beta-sustituida-4-arilo y 21-sustituida 19-norpregnadienodionas como agentes antiprogestacionales
US7250408B2 (en) * 2002-12-16 2007-07-31 Bayer Schering Pharma Ag Glucocorticoid receptor antagonists for prophylaxis and therapy of glucocorticoid-mediated hypogonadism, of sexual dysfunction and/or infertility
EP1613640A4 (en) * 2003-02-28 2010-05-19 Us Gov Health & Human Serv PROCESS FOR PREPARING 17 ALPHA-ACETOXY-11 BETA- (4-N, N-DIMETHYLAMINOPHENYL) -19-NORPREGNA-4,9-DIENE-3,20-DION, INTERMEDIATE PRODUCTS AND METHOD OF MANUFACTURING THESE INTERMEDIATE PRODUCTS
CN101014349A (zh) * 2003-06-20 2007-08-08 病毒基因混和公司 抗病毒组合物及其使用方法
TWI477276B (zh) 2008-04-28 2015-03-21 Repros Therapeutics Inc 抗黃體素給藥方案
DE102009034525A1 (de) * 2009-07-21 2011-01-27 Bayer Schering Pharma Aktiengesellschaft 17-Hydroxy-17-pentafluorethyl-estra-4,9(10)-dien-11-aryl-Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung zur Behandlung von Krankheiten
EP2550288A1 (en) * 2010-03-22 2013-01-30 Repros Therapeutics Inc. Compositions and methods for non-toxic delivery of antiprogestins
US11103514B2 (en) 2010-05-26 2021-08-31 Corcept Therapeutics, Inc. Treatment of muscular dystrophy
BR112014029131B1 (pt) 2012-05-31 2021-03-09 Allergan Pharmaceuticals International Limited cápsula de mucoadesivo
CA2888377C (en) 2012-11-02 2021-02-02 Repros Therapeutics Inc. Methods and compositions for treating progesterone-dependent conditions
EP3079475B1 (en) * 2013-12-11 2020-10-07 Sloan-kettering Institute For Cancer Research Glucocorticoid inhibitors for treatment of prostate cancer
JP6821582B2 (ja) 2015-03-02 2021-01-27 コーセプト セラピューティクス， インコーポレイテッド Ａｃｔｈ分泌腫瘍を処置するための糖質コルチコイドレセプターアンタゴニストおよびソマトスタチンアナログの使用
EP3277281B1 (en) 2015-03-30 2022-01-05 Corcept Therapeutics, Inc. Use of glucocorticoid receptor antagonists in combination with glucocorticoids to treat adrenal insufficiency
WO2017027851A1 (en) 2015-08-13 2017-02-16 Corcept Therapeutics, Inc. Method for differentially diagnosing acth-dependent cushing's syndrome
JP6995757B2 (ja) 2015-12-23 2022-01-17 オリック ファーマシューティカルズ，インク． グルココルチコイド受容体の阻害剤
US11110103B2 (en) 2015-12-23 2021-09-07 Oric Pharmaceuticals, Inc. Inhibitors of glucocorticoid receptor
CN108699102A (zh) 2015-12-23 2018-10-23 欧瑞克制药公司 糖皮质激素受体抑制剂
WO2017127448A1 (en) 2016-01-19 2017-07-27 Corcept Therapeutics, Inc. Differential diagnosis of ectopic cushing's syndrome
EP3523315B1 (en) 2016-10-07 2021-03-24 Oric Pharmaceuticals, Inc. Inhibitor of glucocorticoid receptor
AU2018244928B2 (en) 2017-03-31 2023-10-19 Corcept Therapeutics, Inc. Glucocorticoid receptor modulators to treat cervical cancer
US11213526B2 (en) 2017-06-20 2022-01-04 Corcept Therapeutics, Inc. Methods of treating neuroepithelial tumors using selective glucocorticoid receptor modulators
EP4263807A2 (en) 2020-12-18 2023-10-25 Instil Bio (Uk) Limited Processing of tumor infiltrating lymphocytes

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH571537A5 (ja) * 1970-04-24 1976-01-15 Sandoz Ag
CH558346A (de) * 1971-06-17 1975-01-31 Sandoz Ag Verfahren zur herstellung neuer 3-oximino-17(alpha)-propadienyl-substituierter steroide.
BE787898A (fr) * 1971-08-26 1973-02-23 Roussel Uclaf Nouveaux composes steroides trieniques et procede de preparation
DE2636405C2 (de) * 1976-08-12 1982-07-08 Schering Ag, 1000 Berlin Und 4619 Bergkamen Δ↑1↑↑5↑-17α-Chloräthinyl- und -Propinylsteroide der Östranreihe, Verfahren zu ihrer Herstellung sowie diese enthaltende pharmazeutische Präparate
FR2377417A1 (fr) * 1977-01-13 1978-08-11 Roussel Uclaf Nouveaux derives steroides substitues en 11b, ainsi que leur procede de preparation
FR2377418A1 (fr) * 1977-01-13 1978-08-11 Roussel Uclaf Nouveaux derives steroides 4,9-dieniques 11b-substitues, leur procede de preparation et leur application comme medicaments
FR2377419A1 (fr) * 1977-01-13 1978-08-11 Roussel Uclaf Nouveaux derives steroides 11b-substitues 1,3,5 (10) trieniques, leur procede de preparation et leur application comme medicament
FR2495621A1 (fr) * 1980-12-05 1982-06-11 Roussel Uclaf Nouveaux derives de l'estra 4,9-diene, leur procede de preparation et leur application comme medicaments
ZA8231B (en) * 1981-01-09 1982-11-24 Roussel Uclaf New 11 -substituted steroid derivatives, their preparation, their use as medicaments, the compositions containing them and the new intermediates thus obtained

Also Published As

Publication number Publication date
CA1206471A (fr) 1986-06-24
GB2118186A (en) 1983-10-26
CH657368A5 (fr) 1986-08-29
ES520195A0 (es) 1983-12-01
FR2522328A1 (fr) 1983-09-02
FI830652A0 (fi) 1983-02-28
EG15881A (en) 1991-06-30
JPH02275895A (ja) 1990-11-09
FR2522328B1 (fr) 1986-02-14
FI80049B (fi) 1989-12-29
MX7199E (es) 1987-12-23
DK89783A (da) 1983-09-02
KR880001870B1 (ko) 1988-09-23
US4540686A (en) 1985-09-10
DE3307143A1 (de) 1983-09-08
ES8401495A1 (es) 1983-12-01
SE8300308L (sv) 1983-09-02
AU562739B2 (en) 1987-06-18
IT1197592B (it) 1988-12-06
AU1191383A (en) 1983-09-08
HU193269B (en) 1987-09-28
YU47883A (en) 1986-04-30
IE54748B1 (en) 1990-01-31
LU84667A1 (fr) 1983-09-08
IL67920A0 (en) 1983-06-15
PT76307B (fr) 1986-01-27
AT396109B (de) 1993-06-25
DK89783D0 (da) 1983-02-25
JPH0443920B2 (ja) 1992-07-20
KR840003649A (ko) 1984-09-15
JPH054397B2 (ja) 1993-01-19
WO1983003099A1 (en) 1983-09-15
IT8347820A0 (it) 1983-02-28
FI830652L (fi) 1983-09-02
ZA83982B (en) 1984-03-28
PT76307A (fr) 1983-03-01
GR78465B (ja) 1984-09-27
FI80049C (fi) 1990-04-10
GB8305558D0 (en) 1983-03-30
SU1340593A3 (ru) 1987-09-23
IE830429L (en) 1983-09-01
MA19716A1 (fr) 1983-10-01
BE896042A (fr) 1983-08-29
SE8300308D0 (sv) 1983-01-21
ATA71183A (de) 1992-10-15
JPS58201800A (ja) 1983-11-24
GB2118186B (en) 1986-04-23
NL8300738A (nl) 1983-10-03
AR241187A1 (es) 1992-01-31
US4477445A (en) 1984-10-16

Similar Documents

Publication Publication Date Title
PH21308A (en) 3-keto-19-nor-/4,9-steroids
CS725784A2 (en) Zpusob vyroby derivatu 4-fenyl-1,3-dioxan-cis-5-ylalkenovych kyselin
CS997683A2 (en) Zpusob vyroby derivatu 1,4:3,6-dianhydrohexitolu
GB2127807B (en) 2,5-piperazinediones
DE3380304D1 (en) 6-substituted-quinoline-5,8-quinones
CS291184A2 (en) Zpusob vyroby 1,8-dihydroxy-10-acyl-9-anthronu
GB8319859D0 (en) 1,1,1-azidodinitro compounds
GB8301383D0 (en) 3,3-dialkyl-and 3,3-alkylene-indoline derivatives
CS108283A2 (en) Rizeni kloubu ctyrnapravovych kolejovych vozidel, zejmena vozu mestske dopravy
GB2127815B (en) 6-anilino-5,8-quinoxalinediones
CS912983A2 (en) Zpusob vyroby l,2 dichlorethanu
GB2127813B (en) 7-anilinoisoquinoline-5, 8-quinones
CS70783A1 (en) Hydraulicke drapakove zarizeni, zajistujici spolehlive udrzeni nakladu
CS546582A1 (en) Zpusob pripravy farmakologicky ucinnych derivatu 1,4 diaminoantrachinonu
CS980483A2 (en) Zpusob vyroby 1,2 dichlorethanu
ZA832310B (en) 1,3,5-triacrylylhexahydro-s-triazine derivatives
CS1024484A2 (en) Zpusob vyroby 3,4,5 trimethoxybenzonitrilu
CS952182A1 (en) Sposob vyroby2,6,6 tetrametyl 4 piperdonu
CS623382A1 (en) Zpusob chemicke rafinace technickeho 2,6 xylenolu
CS581182A1 (en) Zpusob rafinace technickeho 2,6 xylenolu
CS592584A1 (en) Zpusob rafinace 2,6 xylenolu
CS802682A1 (en) Sposob pripravy 2,3,5 trimetylhydrochinonu
CS686884A2 (en) Zpusob vyroby 1,2 dichlorethanu
CS770684A2 (en) Zpusob vyroby novych derivatu 1,4 dihydropyridinu
IL81912A0 (en) 1,2-benzoxathiin-8-ylsulfonylisocyanates,-thioisocyanates,-chlorides and-carbamates and-sulfonamides